Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/Simvastatin vs Atorvastatin vs Rosuvastatin for LDL-C Reduction in High Risk Patients
NCT00462748Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Mar 2007
- Primary completion
- Jun 2008
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, randomised, double-blind trial of Vytorin in hypercholesterolemia (3 arms), sponsored by Organon & Co. Primary endpoint: Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at 6 weeks. Started Mar 2007; status: completed.
02
Drugs
Vytorin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00462748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462748.